Lowest Price Guaranteed From USD 2,499
Published
February 2017
Pages
235
View Count
3993
Deep learning is a novel machine learning technique that can be used to generate relevant insights from large volumes of data. The term Deep Learning was coined in 2006 by Geoffrey Hinton to refer to algorithms that enable computers to analyze objects and text in videos and images. Fundamentally, deep learning algorithms are designed to analyze and use large volumes of data to improve the capabilities of machines. Companies, such as Google, Amazon, Facebook, LinkedIn, IBM and Netflix, are already using deep learning algorithms to analyze users activities and make customized suggestions and recommendations based on individual preferences. Today, in many ways, deep learning algorithms have enabled computers to see, read and write. In light of recent advances, the error rate associated with machines being able to analyze and interpret medical images has come down to 6%, which, some research groups claim, is even better than humans.
The applications of the technology are being explored across a variety of areas. Specifically in healthcare, the American Recovery and Reinvestment Act of 2009 and the Precision Medicine Initiative of 2015 have widely endorsed the value of medical data in healthcare. Owing to several such initiatives, medical big data is expected to grow approximately 50-fold to reach 25,000 petabytes by 2020. Since 80% of this is unstructured, it is difficult to generate valuable / meaningful insights using conventional data mining techniques. In such cases, deep learning has emerged as a novel solution. Lead identification and optimization in drug discovery, support in patient recruitment for clinical trials, medical image analysis, biomarker identification, drug efficacy analysis, drug adherence evaluation, sequencing data analysis, virtual screening, molecule profiling, metabolomic data analysis, EMR analysis and medical device data evaluation are examples of applications where deep learning based solutions are being explored.
The likely benefits associated with the use of deep learning based solutions in the above mentioned areas is estimated to be worth multi billion dollars. There are well-known references where deep learning models have accelerated the drug discovery process and provided solutions to precision medicine. With potential applications in drug repurposing and preclinical research, deep learning in drug discovery is likely to have great opportunity. In diagnostics, an increase in the speed of diagnosis is likely to have a profound impact in regions with large patient to physician ratios. The implementation of such solutions is anticipated to increase the efficiency of physicians providing a certain amount of relief to the overly-burdened global healthcare system.
Scope of the Report
The “Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035” report examines the current landscape and future outlook of the growing market of deep learning solutions within the healthcare domain. Primarily driven by the big data revolution, deep learning algorithms have emerged as a novel solution to generate relevant insights from medical data. This continuing shift towards digitalization of healthcare system has been backed by a number of initiatives taken by the government, and has also sparked the interest of several industry / non-industry players. The involvement of global technology companies and their increasing collaborations with research institutes and hospitals are indicative of the research intensity in this field. At the same time, the pharma giants have been highly active in adopting the digital models. Companies such as AstraZeneca, Pfizer and Novartis continue to evaluate the digital health initiatives across drug discovery, clinical trial management and medical diagnosis. Some notable examples of such digital health initiatives include GSK and Pfizer’s collaboration with Apple for the use of the latter’s research kit in clinical trials, Biogen’s partnership with Fitbit for using smart wearables in clinical trial management, and Teva Pharmaceuticals’ partnership with American Well to use Smart Inhalers for patients with asthma and COPD.
Backed by funding from several Venture Capital firms and strategic investors, deep learning has emerged as one of the most widely explored initiatives within digital healthcare. The current generation of deep learning models are flexible and have the ability to evolve and become more efficient over time. Despite being a relatively novel field of research, these models have already demonstrated significant potential in the healthcare industry.
One of the key objectives of this study was to identify the various deep learning solutions that are currently available / being developed to cater to unmet medical needs, and also evaluate the future prospects of deep learning within the healthcare industry. These solutions are anticipated to open up significant opportunities in the field of drug discovery and diagnostics as the healthcare industry gradually shifts towards digital solutions. In addition to other elements, the study covers the following:
For the purpose of the study, we invited over 100 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Mausumi Acharya (CEO, Advenio Technosys), Carla Leibowitz (Head of Strategy and Marketing, Arterys) and Deekshith Marla (CTO, Arya.ai).
Chapter 2 provides an executive summary of the report. It offers a high level view on where the deep learning market for drug discovery and diagnostics is headed in the long term.
Chapter 3 is an introductory chapter that presents details on the digital revolution in the medical industry. It elaborates on the growth of artificial intelligence and machine learning tools, such as deep learning algorithms, along with a discussion on their potential applications in solving some of the key challenges faced by the healthcare industry. The chapter also gives an overview on the rise of big data and its role in providing personalized and evidence based care to patients.
Chapter 4 includes information on close to 100 companies that are evaluating potential applications of their proprietary deep learning solutions in the healthcare industry. The classification system used for these solutions was based on their application areas. These include drug discovery, diagnostics, clinical trial management and drug adherence programs. In addition, we have highlighted specific geographical pockets that we identified as innovation hubs in this sector.
Chapter 5 provides detailed profiles of some of the key stakeholders in this space with detailed information on their technologies, funding, collaborations and partnerships, intellectual capital, awards and recognition and activity on social media.
Chapter 6 presents a case study on two technology giants in this field, namely IBM and Google. It provides a detailed description of the initiatives being undertaken by these companies to explore the applications of deep learning in the medical field. In addition, the chapter provides a comparison of the two companies based on their respective deep learning expertise, and partnerships and acquisitions.
Chapter 7 provides information on the various investments that have been made into this industry. Our analysis revealed interesting insights on the growing interest of venture capitalists and other stakeholders in this market. In addition, we identified some of the key investors in this market.
Chapter 8 presents detailed projections related to the growth of the deep learning industry in healthcare from 2017 to 2035. To quantify the opportunity for deep learning in the drug discovery space, we have provided optimistic and conservative forecast scenarios, along with our base forecast to account for the uncertainties associated with the adoption of these technologies. The insights presented in this chapter are backed by data from close to 50 countries and highlights the opportunity for deep learning companies in diagnostics within the same regions.
Chapter 9 features a comprehensive valuation analysis of the companies that are developing deep learning solutions for applications in drug discovery and diagnostics. The chapter provides insights based on a multi-variable dependent valuation model. The model is based on the future potential of the companies’ technologies, their current popularity, funding received, year of establishment and the employed workforce in these companies.
Chapter 10 presents the opinions expressed by selected key opinion leaders on the applications and challenges associated with deep learning in the healthcare sector. The chapter provides key takeaways from presentations and videos of these experts, highlighting the future opportunity for these models within the healthcare industry.
Chapter 11 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in the previous chapters.
Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in this market. We have presented the details of our discussions with Mausumi Acharya (CEO, Advenio Technosys), Carla Leibowitz (Head of Strategy and Marketing, Arterys), and Deekshith Marla (CTO, Arya.ai).
Chapter13 is an appendix, which provides tabulated data and numbers for all the figures in the report. In addition, the chapter includes a detailed analysis of the survey conducted with several companies to estimate the opportunity for deep learning in drug discovery and diagnostics.
Chapter 14 is an appendix, which provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Humans, Machines and Intelligence
3.2. Artificial Intelligence
3.3. The Science of Learning
3.3.1. Teaching Machines
3.3.1.1. Machines for Computing
3.3.1.2. Understanding Human Brain: Way to Artificial Intelligence
3.4. The Big Data Revolution
3.4.1. Big Data: An Introduction
3.4.2. Big Data: Internet of Things (IoT)
3.4.3. Big Data: A Growing Trend
3.4.4. Big Data: Application Areas
3.4.4.1. Big Data Analytics in Healthcare: Collaborating For Value
3.4.4.2. Machine Learning
3.4.4.3. Deep Learning: The Amalgamation of Machine Learning and Big Data
3.5. Deep Learning in Healthcare
3.5.1. Personalized Medicine
3.5.2. Lifestyle Management
3.5.3. Wearable Devices
3.5.4. Drug Discovery
3.5.5. Clinical Trial Management
3.5.6. Diagnostics
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Deep Learning in Drug Discovery and Diagnostics: Market Landscape
4.2.1. Deep Learning in Drug Discovery and Diagnostics: Distribution by Specialization
4.2.2. Deep Learning in Drug Discovery and Diagnostics: Distribution by Geographical Location
4.2.3. Deep Learning in Drug Discovery and Diagnostics: Distribution by Year of Establishment
4.3. Deep Learning in Drug Discovery
4.3.1. Deep Learning in Drug Discovery: Distribution by Type of Solution
4.3.2. Deep Learning in Drug Discovery: Distribution by Area of Focus
4.3.3. Deep Learning in Drug Discovery: Distribution by Therapeutic Area
4.3.4. Deep Learning in Drug Discovery: Regional Mapping
4.4. Deep Learning in Diagnostics
4.4.1. Deep Learning in Diagnostics: Distribution by Type of Solution
4.4.2. Deep Learning in Diagnostics: Distribution by Type of Input Data
4.4.3. Deep Learning in Diagnostics: Distribution by Therapeutic Area
4.4.4. Deep Learning in Diagnostics: Regional Mapping
4.5. Deep Learning in Drug Discovery and Diagnostics
4.5.1. Deep Learning in Drug Discovery and Diagnostics: Regional Mapping
4.6. Deep Learning in Drug Discovery and Diagnostics: Non-Industry Players
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Advenio Technosys
5.2.1. Company Overview
5.2.2. Technology and Services
5.2.3. Venture Funding
5.2.4. Intellectual Capital
5.2.5. Awards and Achievements
5.2.6. Social Media Activity
5.3. AiCure
5.3.1. Company Overview
5.3.2. Technology and Services
5.3.3. Venture Funding
5.3.4. Intellectual Capital
5.3.5. Awards and Achievements
5.3.6. Social Media Activity
5.4. Atomwise
5.4.1. Company Overview
5.4.2. Technology and Services
5.4.3. Venture Funding
5.4.4. Intellectual Capital
5.4.5. Social Media Analysis
5.5. BenevolentAI
5.5.1. Company Overview
5.5.2. Technology and Services
5.5.3. Venture Funding
5.5.4. Social Media Activity
5.6. Butterfly Network
5.6.1. Company Overview
5.6.2. Technology and Services
5.6.3. Venture Funding
5.6.4. Intellectual Capital
5.6.5. Awards and Achievements
5.6.6. Social Media Activity
5.7. Enlitic
5.7.1. Company Overview
5.7.2. Technology and Services
5.7.3. Venture Funding
5.7.4. Intellectual Property
5.7.5. Awards and Achievements
5.7.6. Social Media Activity
5.8. Human Longevity
5.8.1. Company Overview
5.8.2. Technology and Services
5.8.3. Venture Funding
5.8.4. Intellectual Capital
5.8.5. Awards and Achievements
5.8.6. Social Media Activity
5.9. InSilico Medicine
5.9.1. Company Overview
5.9.2. Technology and Services
5.9.3. Venture Funding
5.9.4. Intellectual Capital
5.9.5. Awards and Achievements
5.9.6. Social Media Activity
5.10. twoXAR
5.10.1. Company Overview
5.10.2. Technology and Services
5.10.3. Venture Funding
5.10.4. Intellectual Capital
5.10.5. Social Media Activity
5.11. Zebra Medical Vision
5.11.1. Company Overview
5.11.2. Technology and Services
5.11.3. Venture Funding
5.11.4. Intellectual Capital
5.11.5. Social Media Activity
6. CASE STUDY: IBM WATSON VERSUS GOOGLE DEEPMIND
6.1. Chapter Overview
6.2. IBM
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. IBM Watson
6.3. Google
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Google DeepMind
6.4. IBM v/s Google: Artificial Intelligence Acquisitions Portfolio
6.5. IBM v/s Google: Healthcare Partnerships and Collaborations
6.6. IBM v/s Google: Future Outlook and Primary Concerns
7. CAPITAL INVESTMENTS AND FUNDING
7.1. Chapter Overview
7.2. Deep Learning Market: Funding Instances
7.2.1. Funding Instances: Distribution by Year
7.2.2. Funding Instances: Distribution by Type of Funding
7.2.3. Leading Deep Learning Companies: Evaluation by Number of Funding Instances
7.2.4. Leading VC Firms / Investors: Evaluation by Number of Funding Instances
8. OPPORTUNITY ANALYSIS
8.1. Chapter Overview
8.2. Opportunity for Deep Learning in Drug Discovery
8.2.1. Forecast Methodology
8.2.2. Key Assumptions
8.2.3. Overall Deep Learning Market in Drug Discovery, 2017-2035
8.2.4. Comparative Summary
8.3. Opportunity for Deep Learning in Diagnostics
8.3.1. Forecast Methodology
8.3.2. Key Assumptions
8.3.3. Overall Deep Learning Market in Diagnostics, 2017-2035
8.4. Overall Deep Learning Market in Drug Discovery and Diagnostics, 2017-2035
9. COMPANY VALUATION ANALYSIS
9.1. Chapter Overview
9.2. Company Valuation: Methodology
9.3. Company Valuation: Categorization by Multiple Parameters
9.3.1. Categorization by Twitter Score
9.3.2. Categorization by Followers Score
9.3.3. Categorization by Google Hits Score
9.3.4. Categorization by Uniqueness Score
9.3.5. Categorization by Website Score
9.3.6. Categorization by Awards Score
9.3.7. Categorization by Weighted Average Score
9.3.8. Company Valuation: Roots Analysis Proprietary Scores
10. DEEP LEARNING IN HEALTHCARE: EXPERT INSIGHTS
10.1. Chapter Overview
10.2. Industry Experts
10.2.1. Alex Jaimes, CTO, AiCure
10.2.2. Jeremy Howard, Founder, Enlitic
10.2.3. Riley Doyle, CEO, Desktop Genomics
10.3. University and Hospital Experts
10.3.1. Dr. Steven Alberts, Chairman of Medical Oncology, Mayo Clinic
10.3.2. Neil Lawrence, Professor, University of Sheffield
10.3.3. Yoshua Bengio, Professor, Universit de Montral
10.4. Venture Capital Experts
10.4.1. Robert Perl, CEO, Permanente Medical Group; Vinod Khosla, CEO, Khosla Ventures; Abraham Verghese, Professor, Stanford School of Medicine
10.5. Other Expert Opinions
11. CONCLUSION
11.1. Big Data and Deep Learning are Touted as the Next Big Thing in Digital Healthcare
11.2. The Field is Witnessing Rising Interest from Technology and Pharmaceutical Giants
11.3. Drug Discovery and Diagnostics have Emerged as the Major Application Areas for Deep Learning in Healthcare
11.4. Start-ups, Backed by Venture Capital Investors, are Driving Innovation in the Market
11.5. The Applications of Deep Learning are Expected to Result in Significant Time and Cost Savings
11.6. Data Sharing and Security Pose the Biggest Hurdles to the Implementation of Deep Learning Solutions
11.7. Certain Regulatory and Socio-Economic Concerns have Emerged as Additional Roadblocks in this Domain
12. INTERVIEW TRANSCRIPTS
12.1. Mausumi Acharya, CEO, Advenio Technosys
12.2. Carla Leibowitz, Head of Strategy and Marketing, Arterys
12.3. Deekshith Marla, CTO, Arya.ai and Sanjay Bhadra, COO, Arya.ai
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Observational Learning: Key Stages of Learning
Figure 3.2 Understanding Neurons and the Human Brain: Key Scientific Contributors
Figure 3.3 Big Data: The Three V’s
Figure 3.4 Internet of Things: Illustrative Framework
Figure 3.5 Internet of Things: Applications in Healthcare
Figure 3.6 Big Data: Google Trends
Figure 3.7 Big Data: Application Areas
Figure 3.8 Big Data: Opportunities in Healthcare
Figure 3.9 Machine Learning Algorithm: Workflow
Figure 3.10 Machine Learning Algorithms: Timeline
Figure 3.11 Neural Networks: Architecture
Figure 3.12 Deep Learning: Image Recognition
Figure 3.13 Google Trends: Artificial Intelligence v/s Machine Learning v/s Deep Learning v/s Cognitive Computing
Figure 3.14 Google Trends: Popular Keywords (Deep Learning)
Figure 3.15 Deep Learning Frameworks: Relative Performance
Figure 3.16 Personalized Medicine: Applications in Healthcare
Figure 4.1 Deep Learning in Drug Discovery and Diagnostics: Distribution by Specialization and Type
Figure 4.2 Deep Learning in Drug Discovery and Diagnostics: Distribution by Geographical Location and Area of Specialization
Figure 4.3 Deep Learning in Drug Discovery and Diagnostics: Distribution by Founding Year and Specialization
Figure 4.4 Deep Learning in Drug Discovery: Distribution by Type of Solution
Figure 4.5 Deep Learning in Drug Discovery: Distribution by Focus Area
Figure 4.6 Deep Learning in Drug Discovery: Distribution by Therapeutic Area
Figure 4.7 Deep Learning in Drug Discovery: Regional Mapping
Figure 4.8 Deep Learning in Diagnostics: Distribution by Type of Solution
Figure 4.9 Deep Learning in Diagnostics: Distribution by Type of Input Data
Figure 4.10 Deep Learning in Diagnostics: Distribution of Service Providers by Key Modifications
Figure 4.11 Deep Learning in Diagnostics: Distribution by Therapeutic Area
Figure 4.12 Deep Learning in Diagnostics: Regional Mapping
Figure 4.13 Deep Learning in Drug Discovery and Diagnostics: Geographical Distribution
Figure 4.14 Deep Learning in Drug Discovery and Diagnostics, Non-Industrial Players: Regional Mapping
Figure 5.1 Advenio Technosys: Company Overview
Figure 5.2 Advenio Technosys: Social Media Analysis
Figure 5.3 AiCure: Company Overview
Figure 5.4 AiCure: Social Media Analysis
Figure 5.5 Atomwise: Company Overview
Figure 5.6 BenevolentAI: Company Overview
Figure 5.7 BenevolentAI: Social Media Analysis
Figure 5.8 Butterfly Network: Company Overview
Figure 5.9 Butterfly Network: Social Media Analysis
Figure 5.10 Enlitic: Company Overview
Figure 5.11 Enlitic: Social Media Analysis
Figure 5.12 Human Longevity: Company Overview
Figure 5.13 Human Longevity: Social Media Analysis
Figure 5.14 InSilico Medicine: Company Overview
Figure 5.15 InSilico Medicine: Social Media Analysis
Figure 5.16 twoXAR: Company Overview
Figure 5.17 twoXAR: Social Media Analysis
Figure 5.18 Zebra Medical Vision: Company Overview
Figure 5.19 Zebra Medical Vision: Social Media Analysis
Figure 6.1 IBM: Annual Revenues, 2011-Q3 2016 (USD Billion)
Figure 6.2 Alphabet: Annual Revenues, 2011-Q3 2016 (USD Billion)
Figure 6.3 IBM versus Google: Acquisition Trend (Artificial Intelligence), 2011-2016
Figure 7.1 Funding Instances: Distribution by Year, 2007-2016
Figure 7.2 Funding Instances: Amount Invested Per Year (USD Million), 2007-2016
Figure 7.3 Funding Instances: Distribution by Type of Funding, 2007-2016
Figure 7.4 Funding Instances: Distribution by Total Amount Invested in Each Category, 2007-2016 (USD Million)
Figure 7.5 Leading Companies: Evaluation by Number of Funding Instances
Figure 7.6 Leading VC Firms: Evaluation by Number of Instances
Figure 8.1 Drug Approval: Historical Data, 2005-2015
Figure 8.2 Opportunity for Deep Learning in Drug Discovery: Future Market Scenarios
Figure 8.3 Deep Learning Market in Drug Discovery, Short-Midterm (2017-2026): Base Scenario (USD Billion)
Figure 8.4 Deep Learning Market in Drug Discovery, Long Term (2026-2035): Base Scenario (USD Billion)
Figure 8.5 Deep Learning Market in Drug Discovery (2017-2035): Market Scenarios (USD Billion)
Figure 8.6 Deep Learning in Diagnostics: Distribution of Radiologists (per 100,000 population), High Income Countries
Figure 8.7 Deep Learning in Diagnostics: Distribution of Radiologists (per 100,000 population), Middle Income Countries
Figure 8.8 Deep Learning in Diagnostics: Global Distribution of Radiology Images
Figure 8.9 Deep Learning in Diagnostics: Deep Learning Efficiency Profile
Figure 8.10 Deep Learning Market in Diagnostics, Short-Midterm (2017-2026) (USD Billion)
Figure 8.11 Deep Learning Market in Diagnostics, Long Term (2026-2035): Base Scenario (USD Billion)
Figure 8.12 Deep Learning Market in Diagnostics: Market Distribution
Figure 8.13 Overall Deep Learning Market in Drug Discovery and Diagnostics, (2017-2035): Base Scenario (USD Billion)
Figure 9.1 Company Valuation Analysis: A/F Ratio, Input Dataset
Figure 9.2 Company Valuation Analysis: A/Y Ratio, Input Dataset
Figure 9.3 Company Valuation Analysis: A/E Ratio, Input Dataset
Figure 9.4 Company Valuation Analysis: Categorization by Tweets Score
Figure 9.5 Company Valuation Analysis: Categorization by Followers Score
Figure 9.6 Company Valuation Analysis: Categorization by Google Hits Score
Figure 9.7 Company Valuation Analysis: Categorization by Uniqueness Score
Figure 9.8 Company Valuation Analysis: Categorization by Website Score
Figure 9.9 Company Valuation Analysis: Categorization by Awards Score
Figure 9.10 Company Valuation Analysis: Categorization by Weighted Average Score
Figure 9.11 Company Valuation Analysis: Unicorns in Deep Learning
Figure 11.1 Deep Learning Market in Drug Discovery and Diagnostics, (2017-2035): Base Scenario (USD Billion)
Table 3.1 Machine Learning: A Brief History
Table 4.1 Drug Discovery and Diagnostics: Deep Learning Service Providers
Table 4.2 Deep Learning Industry Players: Drug Discovery
Table 4.3 Deep Learning Industry Players: Diagnostics
Table 4.4 Deep Learning Industry Players: Drug Discovery and Diagnostics
Table 4.5 Deep Learning Non-Industry Players: Drug Discovery and Diagnostics
Table 5.1 Advenio Technosys: Venture Capital Funding
Table 5.2 Advenio Technosys: Patent Portfolio
Table 5.3 AiCure: Venture Capital Funding
Table 5.4 AiCure: Patent Portfolio
Table 5.5 Atomwise: Key Partnerships
Table 5.6 Atomwise: Venture Capital Funding
Table 5.7 Atomwise: Patent Portfolio
Table 5.8 BenevolentAI: Venture Capital Funding
Table 5.9 Butterfly Network: Venture Capital Funding
Table 5.10 Butterfly Network: Patent Portfolio
Table 5.11 Enlitic: Venture Capital Funding
Table 5.12 Human Longevity: Partnerships and Collaborations
Table 5.13 Human Longevity: Venture Capital Funding
Table 5.14 Human Longevity: Patent Portfolio
Table 5.15 InSilico Medicine: Partnerships and Collaborations
Table 5.16 InSilico Medicine: Venture Capital Funding
Table 5.17 InSilico Medicine: Patent Portfolio
Table 5.18 twoXAR: Partnerships and Collaborations
Table 5.19 twoXAR: Venture Capital Funding
Table 5.20 Zebra Medical Vision: Partnerships and Collaborations
Table 5.21 Zebra Medical Vision: Venture Capital Funding
Table 5.22 Zebra Medical Vision: Patent Portfolio
Table 6.1 IBM: Artificial Intelligence Acquisitions
Table 6.2 Google: Artificial Intelligence Acquisitions
Table 6.3 IBM Watson: Collaborations & Partnerships in Healthcare
Table 6.4 Google DeepMind: Collaborations & Partnerships in Healthcare
Table 7.1 List of Funding Instances and Investors Involved
Table 7.2 Deep Learning in Drug Discovery & Diagnostics Market: Types of Funding, 2007- 2016
Table 8.1 Opportunity for Deep Learning in Drug Discovery: Survey Responses
Table 8.2 Opportunity for Deep Learning in Drug Discovery: Forecast Parameters
Table 8.3 Deep Learning in Drug Discovery: Conservative Scenario, Key Parameters
Table 8.4 Deep Learning in Drug Discovery: Base Scenario Parameters
Table 8.5 Deep Learning in Drug Discovery: Optimistic Scenario Parameters
Table 9.1 Company Valuation Analysis: Sample Dataset
Table 9.2 Company Valuation Analysis: Weighted Average Evaluation
Table 9.3 Company Valuation Analysis: Estimated Valuation
Table 9.4 Company Valuation Analysis: Distribution by Specialization
Table 13.1 Deep Learning in Drug Discovery and Diagnostics: Distribution by Specialization
Table 13.2 Deep Learning in Drug Discovery and Diagnostics: Distribution by Service Provider Type
Table 13.3 Deep Learning in Drug Discovery and Diagnostics: Distribution by Geographical Location and Area of Specialization
Table 13.4 Deep Learning in Drug Discovery and Diagnostics: Distribution by Founding Year and Specialization
Table 13.5 Deep Learning in Drug Discovery: Distribution by Type of Solution
Table 13.6 Deep Learning in Drug Discovery: Distribution by Focus Area
Table 13.7 Deep Learning in Drug Discovery: Regional Mapping
Table 13.8 Deep Learning in Diagnostics: Distribution by Type of Solution
Table 13.9 Deep Learning in Diagnostics: Distribution by Type of Input Data
Table 13.10 Deep Learning in Diagnostics: Regional Mapping
Table 13.11 Deep Learning in Drug Discovery and Diagnostics: Regional Mapping
Table 13.12 Deep Learning in Drug Discovery and Diagnostics, Non-Industrial Players: Geographical Distribution
Table 13.13 IBM: Annual Revenues, 2011-Q3 2016 (USD Billion)
Table 13.14 Alphabet: Annual Revenues, 2011-Q3 2016 (USD Billion)
Table 13.15 IBM versus Google: Acquisition Trend (Artificial Intelligence), 2011-2016
Table 13.16 Funding Instances: Distribution by Year, 2007-2016
Table 13.17 Funding Instances: Distribution by Type of Funding, 2007-2016
Table 13.18 Funding Instances: Distribution by Total Amount Invested in Each Category, 2007-2016 (USD Million)
Table 13.19 Leading Companies: Evaluation by Number of Funding Instances
Table 13.20 Leading Companies: Evaluation by Number of Funding Instances
Table 13.21 Drug Approval: Historical Data, 2005-2015
Table 13.22 Deep Learning Market in Drug Discovery, Short-Midterm (2017-2026): Base Scenario (USD Billion)
Table 13.23 Deep Learning Market in Drug Discovery, Long Term (2026-2035): Base Scenario (USD Billion)
Table 13.24 Deep Learning Market in Drug Discovery, Short-Midterm (2017-2026): Optimistic Scenario (USD Billion)
Table 13.25 Deep Learning Market in Drug Discovery, Long Term (2026-2035): Optimistic Scenario (USD Billion)
Table 13.26 Deep Learning Market in Drug Discovery, Short-Midterm (2017-2026): Conservative Scenario (USD Billion)
Table 13.27 Deep Learning Market in Drug Discovery, Long Term (2026-2035): Conservative Scenario (USD Billion)
Table 13.28 Deep Learning Market in Drug Discovery (2017-2035): Market Scenarios (USD Billion)
Table 13.29 Deep Learning in Diagnostics: Distribution of Radiologists (per 100,000 population), High Income Countries
Table 13.30 Deep Learning in Diagnostics: Distribution of Radiologists (per 100,000 population), Middle Income Countries
Table 13.31 Deep Learning in Diagnostics: Deep Learning Efficiency Profile
Table 13.32 Deep Learning Market in Diagnostics, Short-Midterm (2017-2026) (USD Billion)
Table 13.33 Deep Learning Market in Diagnostics, Long Term (2026-2035): Base Scenario (USD Billion)
Table 13.34 Deep Learning Market in Diagnostics: Market Distribution (USD Billion)
Table 13.35 Deep Learning Market in Diagnostics: Market Distribution (USD Billion)
Table 13.36 Company Valuation Analysis: Valuation Ratios, Input Dataset
The following companies and organizations have been mentioned in the report.
Discounts available for multiple report purchases
sales@rootsanalysis.com